GCA
HBIO icon

Greenwood Capital Associates’s Harvard Bioscience HBIO Stock Holding History

Greenwood Capital Associates’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,775
Closed -$18.6K – 299
2025
Q4 		$18.6K Hold
2,775
– – ﹤0.01% 256
2025
Q3 		$12.2K Hold
2,775
– – ﹤0.01% 254
2025
Q2 		$12.3K Sell
2,775
-74
-3% -$309 ﹤0.01% 249
2025
Q1 		$16.1K Sell
2,849
-18,781
-87% -$240K ﹤0.01% 234
2024
Q4 		$456K Sell
21,630
-957
-4% -$22K 0.06% 196
2024
Q3 		$608K Buy
22,587
+1,894
+9% +$55.8K 0.08% 172
2024
Q2 		$590K Sell
20,693
-968
-4% -$34K 0.08% 178
2024
Q1 		$918K Sell
21,661
-399
-2% -$17.9K 0.12% 143
2023
Q4 		$1.18M Sell
22,060
-896
-4% -$40.4K 0.15% 117
2023
Q3 		$987K Buy
22,956
+162
+0.7% +$7.47K 0.14% 130
2023
Q2 		$1.25M Sell
22,794
-4,843
-18% -$266K 0.18% 103
2023
Q1 		$1.16M Sell
27,637
-598
-2% -$17.7K 0.17% 115
2022
Q4 		$782K Buy
28,235
+471
+2% +$11.6K 0.13% 133
2022
Q3 		$711K Sell
27,764
-386
-1% -$12.8K 0.12% 141
2022
Q2 		$1.01M Buy
28,150
+5,852
+26% +$264K 0.16% 111
2022
Q1 		$1.39M Buy
22,298
+662
+3% +$39.2K 0.36% 49
2021
Q4 		$1.52M Buy
21,636
+395
+2% +$28.1K 0.22% 87
2021
Q3 		$1.48M Buy
21,241
+196
+0.9% +$15.6K 0.23% 81
2021
Q2 		$1.75M Sell
21,045
-18
-0.1% -$1.27K 0.27% 74
2021
Q1 		$1.15M Buy
21,063
+291
+1% +$14.2K 0.18% 96
2020
Q4 		$891K Buy
20,772
+5,838
+39% +$218K 0.15% 117
2020
Q3 		$450K Buy
14,934
+3,376
+29% +$114K 0.09% 133
2020
Q2 		$358K Buy
11,558
+705
+6% +$19K 0.08% 126
2020
Q1 		$240K Sell
10,853
-1,743
-14% -$47.2K 0.07% 126
2019
Q4 		$384K Buy
12,596
+2,808
+29% +$80.8K 0.08% 128
2019
Q3 		$301K Buy
9,788
+2,194
+29% +$54.5K 0.07% 134
2019
Q2 		$152K Sell
7,594
-227
-3% -$6.65K 0.04% 171
2019
Q1 		$337K Buy
7,821
+85
+1% +$3.08K 0.09% 119
2018
Q4 		$246K Buy
7,736
+2,265
+41% +$89.3K 0.06% 148
2018
Q3 		$287K Buy
+5,471
New +$307K 0.06% 150

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $100M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Greenwood Capital Associates's HBIO Position: Q1 2026 in Review

Greenwood Capital Associates sold out of Harvard Bioscience (HBIO) in Q1 2026, closing a stake of 2,775 shares — an estimated $18.6K sold.

Greenwood Capital Associates first reported a position in HBIO in Q3 2018 and held it in 30 quarters. The position peaked at $1.75M in Q2 2021. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

  • Greenwood Capital Associates reported no remaining Harvard Bioscience position as of Q1 2026 after selling out during the quarter.
  • Greenwood Capital Associates sold 2,775 Harvard Bioscience shares in Q1 2026, an estimated $18.6K.
  • Greenwood Capital Associates first reported a position in Harvard Bioscience in Q3 2018 and held it in 30 quarters.
  • Greenwood Capital Associates's Harvard Bioscience position peaked at $1.75M in Q2 2021.
  • 36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Greenwood Capital Associates's 13F filing for Q1 2026, filed 29 Apr 2026.